Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (ZBH) is a global innovator in musculoskeletal healthcare, delivering advanced orthopedic solutions for nearly a century. This news hub provides investors and medical professionals with timely updates on product developments, regulatory milestones, and strategic initiatives shaping the future of surgical care.
Track critical updates including quarterly earnings, FDA clearances for robotic surgery systems, and partnerships advancing AI-driven orthopedic solutions. Our curated feed consolidates press releases about joint reconstruction technologies, trauma care innovations, and global market expansions to inform your analysis of this medtech leader.
Discover how Zimmer Biomet’s integration of digital surgery platforms with traditional orthopedic expertise continues to redefine patient outcomes. Bookmark this page for direct access to verified updates about ZBH’s clinical advancements, without promotional commentary or speculative content.
Zimmer Biomet (NYSE: ZBH) has announced a definitive agreement to acquire Monogram Technologies (NASDAQ: MGRM) for an upfront payment of $4.04 per share, representing an equity value of approximately $177 million. The deal includes a CVR worth up to $12.37 per share tied to development milestones through 2030.
The acquisition will expand Zimmer Biomet's ROSA® Robotics platform with Monogram's semi- and fully autonomous robotic technologies. Monogram's FDA-cleared CT-based, semi-autonomous AI-navigated total knee arthroplasty technology is expected to be commercialized with Zimmer Biomet implants in early 2027. The deal positions Zimmer Biomet to potentially become the first company to offer fully autonomous surgical robots in orthopedics.
The transaction is expected to be neutral to adjusted EPS in 2025-2027 and accretive thereafter, with revenue growth contribution beginning in 2027. The deal is anticipated to close later in 2025, subject to regulatory and shareholder approvals.
Zimmer Biomet (NYSE:ZBH) has scheduled its second quarter 2025 financial results conference call and webcast for Thursday, August 7, 2025 at 8:30 a.m. ET. The company will release its quarterly results earlier that day at 6:30 a.m. ET.
Investors can access the live audio webcast through Zimmer Biomet's Investor Relations website. For those preferring to dial in, U.S. and Canadian participants can call (888) 204-4368, while international callers should use +1 (323) 994-2093, both using conference ID 5103691.
Zimmer Biomet (NYSE: ZBH) has appointed Kevin Thornal as Group President, Global Businesses and the Americas, effective July 1, 2025. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Thornal will oversee the Americas commercial organization and lead strategy for global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units.
Thornal brings over 20 years of experience in medical technology, most recently serving as CEO of Nevro Corp. His previous roles include Group President of Global Diagnostic Solutions at Hologic, where he led double-digit growth during the COVID-19 pandemic. He also spent a decade at Stryker Corp., where he achieved sustained double-digit growth as head of North American sales for the Interventional Spine business.
Zimmer Biomet (NYSE and SIX: ZBH) announced that its management team will participate in the Goldman Sachs 46th Annual Global Healthcare Conference. The presentation is scheduled for Monday, June 9, 2025, at 9:20 a.m. ET. Investors and interested parties can access a live webcast of the presentation through Zimmer Biomet's Investor Relations website. The presentation will also be archived for future viewing after the conference.
Zimmer Biomet (NYSE: ZBH) reported its Q1 2025 financial results with net sales of $1.909 billion, showing a 1.1% increase year-over-year and 2.3% growth on a constant currency basis. The company posted net earnings of $182.0 million, with diluted EPS of $0.91 and adjusted EPS of $1.81.
The company updated its full-year 2025 guidance following the Paragon 28 acquisition, projecting reported revenue growth of 5.7% - 8.2% and adjusted EPS of $7.90 - $8.10. Notable highlights include strong performance in U.S. Hips driven by the Z1™ Triple-Taper Femoral Hip System and HAMMR® System, FDA clearance for Persona® Revision SoluTion™ Femur, and the completion of the Paragon 28 acquisition to strengthen their foot and ankle segment.
Geographic performance showed U.S. sales of $1.11 billion (+1.3%) and International sales of $795.5 million (+3.7% constant currency).Zimmer Biomet (NYSE: ZBH) has completed the acquisition of Paragon 28, a specialized medical device company in the foot and ankle orthopedic space. The transaction was finalized on April 21, 2025, with Paragon 28 shareholders receiving $13.00 in cash per share plus a contingent value right (CVR) worth up to $1.00 per share based on revenue milestones.
The acquisition strengthens Zimmer Biomet's position in the $5 billion foot and ankle industry, which is experiencing high-single-digit growth. Key benefits include expanding their technology platform, leveraging Paragon 28's specialized sales organization, and accelerating growth in both U.S. and international markets. The deal also enhances opportunities in the Ambulatory Surgery Center (ASC) space.
Following the acquisition, Paragon 28 has become a wholly-owned subsidiary of Zimmer Biomet, and its shares have ceased trading on the NYSE.
Zimmer Biomet (NYSE: ZBH) has scheduled its first quarter 2025 earnings conference call and webcast for Monday, May 5, 2025, at 8:30 a.m. ET. The company will release its quarterly financial results earlier that day at 6:30 a.m. ET.
The earnings call will be accessible through a live audio webcast on the company's Investor Relations website at https://investor.zimmerbiomet.com, with replay availability after the call. For direct dial-in access, U.S. and Canadian participants can call (888) 204-4368, while international callers should use +1 (323) 994-2093, both using conference ID 5103691.
Zimmer Biomet (NYSE: ZBH) has achieved a significant milestone with CE Mark certification for its RibFix Advantage® Fixation System, marking the first CE Mark approval for an intrathoracic rib fixation system. This innovative system is designed for thoracoscopic fixation, stabilization, and fusion of rib fractures through a minimally invasive approach.
The system features a unique Bridge component that auto-contours to reduce fractures and adapts to rib anatomy during tightening, offering potential benefits of reduced soft tissue disruption compared to traditional open reduction internal fixation. Following its success in the US and other markets, the CE Mark approval enables Zimmer Biomet to distribute the system across the European Economic Area (EEA) and other CE Mark-recognizing markets.
Paragon 28 (NYSE: FNA), a specialized foot and ankle orthopedic medical device company, has announced a significant milestone in its pending acquisition by Zimmer Biomet (NYSE: ZBH). The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired, marking a important step in the regulatory approval process.
The transaction still requires additional approvals, including stockholder approval from Paragon 28 and other regulatory clearances. Both companies anticipate the merger to be completed in the first half of 2025, subject to satisfying remaining closing conditions.
FAQ
What is the current stock price of Zimmer Biomet (ZBH)?
What is the market cap of Zimmer Biomet (ZBH)?
